Primary aldosteronism: an update

References

• Lawes CM, Vander HS, Rodgers A; International Society of Hypertension Global burden of blood-pressure-related disease, 2001. Lancet371(9623), 1513–1518 (2008).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med.351(1), 33–41 (2004).
   PubMed Web of Science ®Google Scholar
• Reynolds RM, Walker BR, Phillips DI et al. Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure. Hypertension53(6), 932–936 (2009).
   PubMed Web of Science ®Google Scholar
• Newton-Cheh C, Guo CY, Gona P et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension49(4), 846–856 (2007).
   PubMed Web of Science ®Google Scholar
• Young WF. Primary aldosteronism: renaissance of a syndrome. Clin. Endocrinol.66(5), 607–618 (2007).
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Yamada T, Yukimura Y et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med.141(12), 1589–1593 (1981).
   PubMed Web of Science ®Google Scholar
• Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. P21(4), 315–318 (1994).
   PubMed Web of Science ®Google Scholar
• Abdelhamid S, Muller-Lobeck H, Pahl S et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch. Intern. Med.156(11), 1190–1195 (1996).
   PubMedGoogle Scholar
• Lim PO, Rodgers P, Cardale K, Watson AD, Macdonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet353(9146), 40 (1999).
   PubMed Web of Science ®Google Scholar
• Fardella CE, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J. Clin. Endocrinol. Metab.85(5), 1863–1867 (2000).
   PubMed Web of Science ®Google Scholar
• Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S. Afr. Med. J.90(4), 394–400 (2000).
   PubMed Web of Science ®Google Scholar
• Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin. Chem.48(11), 1919–1923 (2002).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension Hypertension40(6), 892–896 (2002).
   PubMed Web of Science ®Google Scholar
• Olivieri O, Ciacciarelli A, Signorelli D et al. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J. Clin. Endocrinol. Metab.89(9), 4221–4226 (2004).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol.48(11), 2293–2300 (2006).
   PubMed Web of Science ®Google Scholar
• Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet371(9628), 1921–1926 (2008).
   PubMed Web of Science ®Google Scholar
• Conn J. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA90, 222–225 (1964).
   Google Scholar
• Stowasser M. How common is adrenal-based mineralocorticoid hypertension? Curr. Opin. Enocrinol. Diabetes7, 143–150 (2000).
   Google Scholar
• Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11 β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension Nature355(6357), 262–265 (1992).
   PubMed Web of Science ®Google Scholar
• Sukor N, Mulatero P, Gordon RD et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J. Hypertens.26(8), 1577–1582 (2008).
   PubMed Web of Science ®Google Scholar
• Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab.93(8), 3117–3123 (2008).
   PubMed Web of Science ®Google Scholar
• Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr. Rev.29(2), 133–154 (2008).
   PubMed Web of Science ®Google Scholar
• Davies DL, Beretta-Piccoli C, Brown JJ et al. Body sodium and blood pressure: abnormal and different correlations in Conn’s syndrome, renal artery stenosis and essential hypertension. P. Eur. Dial. Trans.20, 483–488 (1983).
   PubMedGoogle Scholar
• Duprez D, De Buyzere M, Rietzschel ER, Clement DL. Aldosterone and vascular damage. Curr. Hypertens. Rep.2(3), 327–334 (2000).
   PubMedGoogle Scholar
• Funder JW. Steroids, hypertension and cardiac fibrosis. Blood Press. Suppl.2, 39–42 (1995).
   PubMedGoogle Scholar
• Young M, Funder JW. Aldosterone and the heart. Trends Endocrin. Met.11(6), 224–226 (2000).
   PubMed Web of Science ®Google Scholar
• Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension51(2), 432–439 (2008).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Bolognesi M, Rizzoni D et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension51(5), 1366–1371 (2008).
   PubMed Web of Science ®Google Scholar
• Funder JW. Corticosteroid receptors and the central nervous system. J. Steroid. Biochem.49(4–6), 381–384 (1994).
   Google Scholar
• Gomez-Sanchez EP. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology118(2), 819–823 (1986).
   PubMed Web of Science ®Google Scholar
• Young WF Jr. Minireview: primary aldosteronism – changing concepts in diagnosis and treatment. Endocrinology144(6), 2208–2213 (2003).
   PubMed Web of Science ®Google Scholar
• Weber KT, Janicki JS, Pick R, Capasso J, Anversa P. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension Am. J. Cardiol.65(14), 1G–7G (1990).
   Google Scholar
• Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and rennin–angiotensin–aldosterone system. Circulation83(6), 1849–1865 (1991).
   PubMed Web of Science ®Google Scholar
• Williams JS, Williams GH. 50th anniversary of aldosterone. J. Clin. Endocrinol. Metab.88(6), 2364–2372 (2003).
   PubMed Web of Science ®Google Scholar
• White PC. Aldosterone: direct effects on and production by the heart. J. Clin. Endocrinol. Metab.88(6), 2376–2383 (2003).
   PubMed Web of Science ®Google Scholar
• Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc. Res.26(7), 671–671(1992).
   PubMed Web of Science ®Google Scholar
• Keidar S, Kaplan M, Pavlotzky E et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation109(18), 2213–2220 (2004).
   PubMed Web of Science ®Google Scholar
• Duprez DA, De Buyzere ML, Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur. Heart J.19(9), 1371–1376 (1998).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med.341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Williams G, Remme W et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drug Ther.15(1), 79–87 (2001).
   PubMed Web of Science ®Google Scholar
• Beygui F, Collet JP, Benoliel JJ et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation114(24), 2604–2610 (2006).
   PubMed Web of Science ®Google Scholar
• Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol.45(8), 1243–1248 (2005).
   PubMed Web of Science ®Google Scholar
• Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Int. Med.168(1), 80–85 (2008).
   PubMedGoogle Scholar
• Rossi GP, Sacchetto A, Pavan E et al. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation95(6), 1471–1478 (1997).
   PubMed Web of Science ®Google Scholar
• Yoshihara F, Nishikimi T, Yoshitomi Y et al. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension Am. J. Hyperten.9(6), 523–528 (1996).
   PubMed Web of Science ®Google Scholar
• Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension33(1 Pt 2), 232–237 (1999).
   PubMed Web of Science ®Google Scholar
• Fox CS, Larson MG, Hwang SJ et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int.69(11), 2064–2069 (2006).
   PubMed Web of Science ®Google Scholar
• Lai L, Chen J, Hao CM, Lin S, Gu Y. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-β1 pathway in mesangial cells. Biochem. Bioph. Res. Co.348(1), 70–75 (2006).
   PubMed Web of Science ®Google Scholar
• Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-β. Am. J. Physiol. – Renal286(6), F1059–F1062 (2004).
   PubMed Web of Science ®Google Scholar
• Miyata K, Rahman M, Shokoji T et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J. Am. Soc. Nephrol.16(10), 2906–2912 (2005).
   PubMed Web of Science ®Google Scholar
• Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension47(6), 1084–1093 (2006).
   PubMed Web of Science ®Google Scholar
• Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J. Am. Soc. Nephrol.16(11), 3306–3314 (2005).
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J. Am. Soc. Nephrol.19(8), 1459–1462 (2008).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Bernini G, Desideri G et al. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension48(2), 232–238 (2006).
   PubMed Web of Science ®Google Scholar
• Sechi LA, Novello M, Lapenna R et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA295(22), 2638–2645 (2006).
   PubMed Web of Science ®Google Scholar
• Freel EM, Ingram M, Fraser R, Dominiczak AF, Davies E, Connell JM. Aldosterone and sodium excess associate with albuminuria and glomerular hyperfiltration in a severely hypertensive cohort from the MRC BRIGHT Study. Hypertension 54 abstract (2009).
   Google Scholar
• Fallo F, Della MP, Sonino N et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am. J. Hypertens.20(8), 855–861 (2007).
   PubMed Web of Science ®Google Scholar
• Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care30(9), 2349–2354 (2007).
   PubMed Web of Science ®Google Scholar
• Luther JM, Gainer JV, Murphey LJ et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension48(6), 1050–1057 (2006).
   PubMed Web of Science ®Google Scholar
• Catena C, Lapenna R, Baroselli S et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab.91(9), 3457–3463 (2006).
   PubMed Web of Science ®Google Scholar
• Freel EM, Tsorlalis IK, Lewsey J et al. Aldosterone status associates with insulin resistance in patients with heart failure-data from the ALOFT study. Heart95, 1920–1924 (2009).
   PubMed Web of Science ®Google Scholar
• Funder JW, Carey RM, Fardella C et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab.93(9), 3266–3281 (2008).
   PubMed Web of Science ®Google Scholar
• Stowasser M, Gordon RD. Primary aldosteronism – careful investigation is essential and rewarding. Mol. Cell. Endocrinol.217(1–2), 33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Alvarez-Madrazo S, Padmanabhan S, Mayosi BM et al. Familial and phenotypic associations of the aldosterone renin ratio. J. Clin. Endocrinol. Metab.94, 4324–4333 (2009).
   PubMed Web of Science ®Google Scholar
• Mulatero P, Rabbia F, Milan A et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension40(6), 897–902 (2002).
   PubMed Web of Science ®Google Scholar
• Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin. Med.5(1), 55–60 (2005).
   PubMed Web of Science ®Google Scholar
• Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrin. Metab. Clin.31(3), 619–632, xi (2002).
   Web of Science ®Google Scholar
• Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension6(5), 717–723 (1984).
   PubMed Web of Science ®Google Scholar
• Gordon RD, Jackson RV, Strakosch CR et al. Aldosterone producing adenoma: fludrocortisone suppression and left adrenal vein catheterisation in definitive diagnosis and management. Aust. NZ J. Med.9(6), 676–682 (1979).
   PubMedGoogle Scholar
• Lyons DF, Kem DC, Brown RD, Hanson CS, Carollo ML. Single dose captopril as a diagnostic test for primary aldosteronism. J. Clin. Endocrinol. Metab.57(5), 892–896 (1983).
   PubMed Web of Science ®Google Scholar
• Mulatero P, Bertello C, Garrone C et al. Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension50(2), e26–e27 (2007).
   PubMed Web of Science ®Google Scholar
• Freel EM, Connell JM. The resurgence of aldosterone in hypertension and cardiovascular disease. Curr. Hypertens. Rev.2, 21–32 (2006).
   Google Scholar
• Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr. Rev.16(4), 460–484 (1995).
   PubMed Web of Science ®Google Scholar
• Kempers MJ, Lenders JW, van Outheusden L et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann. Intern. Med.151(5), 329–337 (2009).
   PubMed Web of Science ®Google Scholar
• Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin. Endocrinol.70(1), 14–17 (2009).
   PubMed Web of Science ®Google Scholar
• Harvey A, Kline G, Pasieka JL. Adrenal venous sampling in primary hyperaldosteronism: comparison of radiographic with biochemical success and the clinical decision-making with “less than ideal” testing. Surgery140(6), 847–853; discussion 853–855 (2006).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Sacchetto A, Chiesura-Corona M et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J. Clin. Endocrinol. Metab.86(3), 1083–1090 (2001).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Pitter G, Bernante P, Motta R, Feltrin G, Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J. Hypertens.26(5), 989–997 (2008).
   PubMed Web of Science ®Google Scholar
• Seccia TM, Miotto D, De Toni R et al. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension53(5), 761–766 (2009).
   PubMed Web of Science ®Google Scholar
• Magill SB, Raff H, Shaker JL et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J. Clin. Endocrinol. Metab.86(3), 1066–1071 (2001).
   PubMed Web of Science ®Google Scholar
• Phillips JL, Walther MM, Pezzullo JC et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J. Clin. Endocrinol. Metab.85(12), 4526–4533 (2000).
   PubMed Web of Science ®Google Scholar
• Catena C, Colussi G, Lapenna R et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension50(5), 911–918 (2007).
   PubMed Web of Science ®Google Scholar
• Assalia A, Gagner M. Laparoscopic adrenalectomy. Brit. J. Surg.91(10), 1259–1274 (2004).
   PubMed Web of Science ®Google Scholar
• Celen O, O’Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch. Surg. Chicago131(6), 646–650 (1996).
   PubMedGoogle Scholar
• Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J. Urology169(1), 32–35 (2003).
   PubMedGoogle Scholar
• Sawka AM, Young WF, Thompson GB et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann. Intern. Med.135(4), 258–256 (2001).
   PubMed Web of Science ®Google Scholar
• Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am. Surgeon71(10), 864–869 (2005).
   PubMed Web of Science ®Google Scholar
• Proye CA, Mulliez EA, Carnaille BM et al. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery124(6), 1128–1133 (1998).
   PubMed Web of Science ®Google Scholar
• Sicca DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail. Rev.10, 23–29 (2005).
   PubMed Web of Science ®Google Scholar
• Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension49(4), 839–845 (2007).
   PubMed Web of Science ®Google Scholar
• Parthasarathy HK, Al-Hashmi K, McMahon AD et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J. Hypertens.28(1), 170–177 (2010).
   PubMed Web of Science ®Google Scholar
• de Gasparo M, Joss U, Ramjoue HP et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther.240(2), 650–656 (1987).
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens.15(8), 709–716 (2002).
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin. Pharmacother.9(4), 509–515 (2008).
   PubMed Web of Science ®Google Scholar
• Lim PO, Young WF, Macdonald TM. A review of the medical treatment of primary aldosteronism. J. Hypertens.19(3), 353–361 (2001).
   PubMed Web of Science ®Google Scholar
• Connell JM, Freel EM. Mineralocorticoid hypertension. In: Oxford Textbook of Endocrinology and Diabetes. Wass J, Stewart PM (Eds). Oxford University Press, Oxford, UK (2009).
   Google Scholar
• Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J. Hypertens.22(5), 863–869 (2004).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J. Hypertens.26(4), 613–621 (2008).
   PubMed Web of Science ®Google Scholar
• Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J. Clin. Endocrinol. Metab.91(4), 1410–1414, (2006).
   PubMed Web of Science ®Google Scholar
• Barr M, MacKenzie SM, Friel EC et al. Polymorphic variation in the 11β-hydroxylase gene associates with reduced 11-hydroxylase efficiency. Hypertension49(1), 113–119 (2007).
   PubMed Web of Science ®Google Scholar
• Freel EM, Ingram M, Wallace AM et al. Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic–pituitary–adrenal axis activity in hypertensive and normotensive subjects. Clin. Endocrinol.68(5), 700–706 (2008).
   PubMed Web of Science ®Google Scholar